Spyre Therapeutics
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
EBITDA | -51,935 | -53,567 | -61,253 | -55,392 |
EBIT | -56,295 | |||
Net Income | -36,717 | -44,773 | -56,296 | -69,028 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -46,563 | -40,994 | -37,199 | -29,421 |
Cash | 81,659 | 48,493 | 89,423 | 71,580 |
Basic Shares | 60,696 | 60,265 | 47,027 | 50,889 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $886 | $886 | $2,329 | $18,739 |
Gross Profit | 886 | -78 | 2,329 | 18,739 |
EBITDA | -207,967 | -242,303 | -82,817 | -64,073 |
EBIT | -128,564 | -243,047 | -84,781 | -65,649 |
Net Income | -208,018 | -338,790 | -83,815 | -65,801 |
Net Change In Cash | 886 | 886 | 2,329 | 18,739 |
Free Cash Flow | -157,410 | -99,910 | -80,182 | -54,289 |
Cash | 89,423 | 188,893 | 34,863 | 15,142 |
Basic Shares | 47,027 | 6,897 | 3,371 | 2,629 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | $0 |
2025-06-30 | -$0.49 |
2025-03-31 | -$0.60 |
2024-12-31 | -$0.81 |
